BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Courcy L, Bezak E, Marcu LG. Gender-dependent radiotherapy: The next step in personalised medicine? Crit Rev Oncol Hematol 2020;147:102881. [PMID: 31991224 DOI: 10.1016/j.critrevonc.2020.102881] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu JJ, De Vivo I, Wu CY, Giovannucci E. Subsequent primary urogenital cancers among childhood and adolescent cancer survivors in the United States. Urol Oncol 2021:S1078-1439(21)00477-4. [PMID: 34810078 DOI: 10.1016/j.urolonc.2021.10.009] [Reference Citation Analysis]
2 Ignat P, Todor N, Ignat RM, Șuteu O. Prognostic Factors Influencing Survival and a Treatment Pattern Analysis of Conventional Palliative Radiotherapy for Patients with Bone Metastases. Curr Oncol 2021;28:3876-90. [PMID: 34677249 DOI: 10.3390/curroncol28050331] [Reference Citation Analysis]
3 Zhang YZ, Ge SJ, Leng QZ, Ma JJ, Liu HC. Preliminary study of the toxicity and radioprotective effects of zymosan in vitro and in vivo. BMC Pharmacol Toxicol 2021;22:16. [PMID: 33731220 DOI: 10.1186/s40360-021-00482-1] [Reference Citation Analysis]
4 Marcu LG. Gender and Sex-Related Differences in Normal Tissue Effects Induced by Platinum Compounds. Pharmaceuticals 2022;15:255. [DOI: 10.3390/ph15020255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Peired AJ, Campi R, Angelotti ML, Antonelli G, Conte C, Lazzeri E, Becherucci F, Calistri L, Serni S, Romagnani P. Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence. Cancers (Basel) 2021;13:4588. [PMID: 34572815 DOI: 10.3390/cancers13184588] [Reference Citation Analysis]
6 Dell'Oro M, Wilson P, Short M, Hua CH, Merchant TE, Bezak E. Normal tissue complication probability modeling to guide individual treatment planning in pediatric cranial proton and photon radiotherapy. Med Phys 2021. [PMID: 34796509 DOI: 10.1002/mp.15360] [Reference Citation Analysis]
7 Haupt S, Caramia F, Klein SL, Rubin JB, Haupt Y. Sex disparities matter in cancer development and therapy. Nat Rev Cancer 2021;21:393-407. [PMID: 33879867 DOI: 10.1038/s41568-021-00348-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
8 Dell'oro M, Short M, Wilson P, Peukert D, Hua C, Merchant TE, Bezak E. Lifetime attributable risk of radiation induced second primary cancer from scattering and scanning proton therapy - A model for out-of-field organs of paediatric patients with cranial cancer. Radiotherapy and Oncology 2022. [DOI: 10.1016/j.radonc.2022.04.027] [Reference Citation Analysis]
9 Dell'Oro M, Short M, Wilson P, Bezak E. Normal tissue tolerance amongst paediatric brain tumour patients- current evidence in proton radiotherapy. Crit Rev Oncol Hematol 2021;164:103415. [PMID: 34242771 DOI: 10.1016/j.critrevonc.2021.103415] [Reference Citation Analysis]
10 Minczeles NS, de Herder WW, Konijnenberg MW, Feelders RA, Brabander T, Hofland J. Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in Men. Clin Nucl Med 2022;Publish Ahead of Print. [DOI: 10.1097/rlu.0000000000004203] [Reference Citation Analysis]